Jan 29 (Reuters) - Immunitybio Inc IBRX.O:
IMMUNITYBIO ANNOUNCES COLLABORATION WITH BEIGENE ON CONFIRMATORY PHASE 3 TRIAL OF ANKTIVA® AND PD-1 CHECKPOINT INHIBITOR COMBINATION IN NON-SMALL CELL LUNG CANCER
IMMUNITYBIO INC - TO SUBMIT BLA IN 2025 BASED ON QUILT 3.055 DATA
IMMUNITYBIO INC - PATENT FOR ANKTIVA AND CPI COMBINATIONS EXTENDS TO 2035
Source text: ID:nBw6YYSLka
Further company coverage: IBRX.O